Galapagos Gets FDA Nod For IND Application On Phase 1/2 ATALANTA-1 Study Of CD19 CAR-T Therapy GLPG5101 In Refractory Non-Hodgkin Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Galapagos NV has received FDA clearance for its IND application for the ATALANTA-1 study, which will evaluate the CD19 CAR-T therapy GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma.
August 23, 2024 | 5:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Galapagos NV has received FDA clearance for its IND application for the ATALANTA-1 study, which will evaluate the CD19 CAR-T therapy GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma.
The FDA clearance for the IND application is a significant regulatory milestone for Galapagos NV, potentially leading to advancements in their CD19 CAR-T therapy GLPG5101. This could positively impact the company's stock price as it progresses in the clinical trial phase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100